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Cardiovascular screening may benefit middle-aged sportsmen, as coronary artery disease
(CAD) is the main cause of exercise-related sudden cardiac death. Arterial stiffness, as
measured by pulse wave velocity (PWV), may help identify sportsmen with subclinical
CAD. We examined the additional value of PWVmeasurements to traditional CAD risk fac-
tors for identifying CAD.
Methods
From the Measuring Athlete’s Risk of Cardiovascular events (MARC) cohort of asymptom-
atic, middle-aged sportsmen who underwent low-dose Cardiac CT (CCT) after routine
sports medical examination (SME), 193 consecutive sportsmen (aged 55±6.6 years) were
included with additional PWVmeasurements before CCT. Sensitivity, specificity and predic-
tive values of PWV values (>8.3 and >7.5m/s) assessed by Arteriograph were used to iden-
tify CAD (coronary artery calcium scoring100 Agatston Units or coronary CT angiography
luminal stenosis50%) and to assess the additional diagnostic value of PWV to estab-
lished cardiovascular risk factors.
Results
Forty-seven sportsmen (24%) had CAD on CCT. They were older (58.9 vs. 53.8 years,
p<0.001), had more hypertension (17 vs. 4%, p=0.003), higher cholesterol levels (5.7 vs.
5.4mmol/l) p=0.048), and more often were (ever) smokers (55 vs. 34%, p=0.008). Mean
PWV was higher in those with CAD (8.9 vs. 8.0 m/s, p=0.017). For PWV >8.3m/s respec-
tively >7.5m/s sensitivity to detect CAD on CT was 43% and 74%, specificity 69% and 45%,
positive predictive value 31% and 30%, and negative predictive value 79% and 84%. Add-
ing PWV to traditional risk factor models did not change the area under the curve (from 0.78
PLOSONE | DOI:10.1371/journal.pone.0131895 July 6, 2015 1 / 10
a11111
OPEN ACCESS
Citation: Braber TL, Prakken NHJ, Mosterd A, Mali
WPTM, Doevendans PAFM, Bots ML, et al. (2015)
Identifying Coronary Artery Disease in Asymptomatic
Middle-Aged Sportsmen: The Additional Value of
Pulse Wave Velocity. PLoS ONE 10(7): e0131895.
doi:10.1371/journal.pone.0131895
Editor: Karen M. Tordjman, Tel Aviv Sourasky
Medical Center, ISRAEL
Received: December 29, 2014
Accepted: June 8, 2015
Published: July 6, 2015
Copyright: © 2015 Braber et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors received no specific funding
for this work.
Competing Interests: The authors have declared
that no competing interests exist.
(95% CI = 0.709-0.848)) to AUC 0.78 (95% CI 0.710-0.848, p = 0.99)) for prediction of CAD
on CCT.
Conclusions
Limited additional value was found for PWV on top of established risk factors to identify
CAD. PWVmight still have a role to identify CAD in middle-aged sportsmen if risk factors
such as cholesterol are unknown.
Introduction
Regular physical activity is key in the prevention of cardiovascular disease, but vigorous exer-
cise is also associated with a higher cardiovascular event risk, particularly in those with known
or unknown cardiac disease [1]. Over 90% of exercise related cardiac arrests occur in men, pre-
dominantly in those aged 45 years and older, and the majority is attributable to coronary artery
disease (CAD) [2, 3].
In a group of 108 recreational Germanmarathon runners aged 50 or more years the coronary
artery calcium burden was higher in marathon runners than in Framingham Risk Score (FRS)
matched controls [4]. During the six years of follow up, cardiovascular events occurred in 8 par-
ticipants, 7 of whom had a CACS higher than 100 Agatston units although their mean FRS placed
them in a low-risk category [5]. It seems that the conventional cardiovascular risk stratification
underestimates the coronary artery calcium burden in this presumably healthy cohort and that
an increased awareness of a potentially higher than anticipated coronary risk is warranted [5].
These facts indicate that early identification of subclinical CAD should be an important goal
in the pre-participation sports evaluation of middle-aged persons. Pre-participation screening
aims to improve the safety of exercise in the fast-growing group of middle-aged sportsmen by
identifying those at increased risk of cardiovascular events. Frequently used risk scores (e.g.
FRS or European Society of Cardiology SCORE) tend to underestimate cardiovascular risk in
these middle-aged sportsmen, as evidenced by the results of the abovementioned Marathon
study [6]. The 2011 European Society of Cardiology position paper on cardiovascular evalua-
tion of middle-aged/senior individuals engaged in leisure time sports activities advocates the
use of maximal exercise testing [7]. However, although electrocardiogram (ECG) interpretation
in sportsmen can be improved using a standardized ECG criteria tool [8], the low positive pre-
dictive value and high false positive rate for CAD of both resting and exercise electrocardiogra-
phy in asymptomatic individuals remains a cause for concern [9, 10]. Although exercise ECG
is not a standard part of routine pre-participation sports screening, it is still frequently per-
formed in the sports medical evaluation (SME) of those aged 45 years and older.
Cardiac CT (CCT), including both non-contrast CT for CACS and contrast-enhanced coro-
nary CT angiography (CCTA), provides direct, non-invasive visualization of the coronary
arteries. Higher CACS independently predicts cardiovascular mortality, and CCTA visual [11,
12], and CCTA characterizes (calcified vs. non-calcified plaque) and quantifies the extent of
the total atherosclerotic burden and severity of any coronary stenosis. However, routine CCT
is not routinely performed in the SME setting because of costs, radiation exposure and the
need for specific equipment and expertise. Pulse wave velocity (PWV) has recently emerged as
a potential new biomarker for prediction of cardiovascular mortality independent of estab-
lished risk factors such as blood pressure and cholesterol [13–15], and normal and reference
values per age category based on a large European cohort have now been established [16].
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In contrast to CCT, measuring arterial stiffness is easy to perform in an outpatient setting.
In addition, increased arterial stiffness measured by means of PWV has been shown to be an
independent predictor of cardiovascular mortality in various populations [17–21]. Numerous
studies have assessed the additional value of carotid-femoral PWV for prediction of cardiovas-
cular events in the general population [14, 22–24]. Several carotid-femoral PWVmethods
(SphygmoCor and Complior) are widely used to determine PWV, although both methods are
observer-dependent and time-consuming [25]. The Arteriograph is a relatively new and opera-
tor-independent device, which uses oscillometric pressure curves registered by an upper arm
blood pressure cuff connected to a piezo-electric sensor to determine blood pressure and PWV
as validated previously [26–28]. It shows comparable results to tonometry (Complior) in
healthy controls and patients with cardiovascular disease, although systematically lower values
(on average 0.8 m/s lower) are found for the Arteriograph in healthy controls [29].
We set out to determine the value of PWV evaluated with the relatively new Arteriograph,
in addition to routinely assessed cardiovascular risk factors (SCORE), to detect CAD on CCT
in asymptomatic middle-aged sportsmen.
Methods
Study population
Participants were consecutively recruited from the Measuring Athlete’s Risk of Cardiovascular
events (MARC) study that evaluates the additional value of CCT (both CACS and CCTA) to
routine SME, including resting and exercise ECG, in asymptomatic sportsmen aged 45 years
and older. Details on the MARC study design have been reported previously [7]. This study
was conducted according to the principles of the Declaration of Helsinki and has been
approved by the regional Medical Ethics Committee (VCMO, Nieuwegein, The Netherlands),
and the local ethics committee of the University Medical Center Utrecht, The Netherlands. All
participants gave written informed consent.
Asymptomatic sportsmen aged 45 years and older, without known cardiovascular disease
(known coronary artery disease, MI, percutaneous coronary intervention, coronary artery
bypass graft surgery, stroke, transient ischemic attack or peripheral artery disease) were
included if they had undergone a SME with exercise ECG that revealed no abnormalities,
according to the responsible physician. Exclusion criteria were known CAD, allergy to contrast
material, and renal impairment. Both competitive and recreational sportsmen were included,
with the majority of them engaged in high-dynamic high-static sports (cycling) and high-
dynamic low-static sports (long distance runners).
Information regarding basic demographic data, cardiovascular risk factors (smoking status,
cholesterol level, hypertension, diabetes, family history), medication use, as well as height,
weight, body mass index (BMI) and blood pressure were obtained at the sports medical depart-
ment. Two blood pressure measurements were obtained with a standard sphygmanometer.
Total cholesterol and creatinine were measured on the day of the CT-scan if there were no
recent values known within the last 6 months. Inclusion criteria for this specific study were
arterial PWVmeasurement on the day of the CT-scan. The participants were asked to refrain
from physical exercise and from consuming caffeine on the day of the CT-scan and PWV
measurements.
Definitions
CAD was defined as a CACS100 AU on non-contrast CT or a50% luminal stenosis on
CCTA. Smoking status was classified into two levels: ever (former and current) smoker and
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never smoker. Hypertension was defined as a resting blood pressure above 140/90 mmHg or
the use of blood pressure lowering medication.
Pulse wave velocity
PWV, brachial blood pressure and heart rate were measured in a supine position using a blood
pressure cuff on the left arm after several minutes of rest just prior to CCT. PWV as a measure
of arterial stiffness was assessed using the Arteriograph system (Tensiomed, Budapest, Hun-
gary). One measurement was performed in each participant by one observer. The measurement
was repeated in 23 (12%) cases of unsuccessful readings. Persistent unsuccessful readings did
not occur. Intra-observer validation in 41 participants showed a good intra-observer agreement
(Pearson’s correlation 0.9, R2 0.8). One observer performed all measurements, and inter-
observer validation was beyond the scope of this study. Normal values in an age-matched pop-
ulation were used to identify abnormal arterial stiffness measurements as a measure for sub-
clinical atherosclerosis [15]. We assessed both a PWV cut-off using the normal value of 8.3 m/s
for the population 50–59 years old (established with carotid-femoral PWVmeasurements)
[15], as well as a PWV cut-off value of 7.5 m/s that was corrected by 0.8 m/s for the numerical
lower Arteriograph PWVmeasurements [29]. PWV was measured as continuous data and
assessed as the percentage of participants with a higher than normal PWV, based on the estab-
lished cut-off value in a population with optimal blood pressure and no identified cardiovascu-
lar risk factors[16], and abovementioned cut-off value corrected for the systematically lower
Arteriograph measurement.
Cardiac CT
Image acquisition was performed with a 256-slice CT system (Brilliance iCT, Philips Health-
care). First a non-contrast prospectively ECG-triggered CCT was acquired to calculate the
CACS. Scan parameters were 120 kV, 60 mAs. Images were reconstructed at a slice thickness
and increment of 3 mm. CACS was quantified as Agatston scores by identifying all regions of
at least 1mm2 with130 Hounsfield units (HU) within the coronary arteries using semi-auto-
matic software (HeartBeat-CS, Philips Healthcare) [30]. CCTA scan parameters were as fol-
lows: 120 kV; 210 mAs; 95–115 ml (depending on weight< or 80 kg) non-ionic contrast
material (Ultravist 300 mg I/ml, iopromide) injected at a speed of 6–6.7 ml/s followed by 30–
40 ml saline injected at the same flow rate. The CCTA was acquired with prospective ECG trig-
gering at a mid-diastolic phase (78%). Participants with a heart rate of more than 65 beats/min
received 5 to 20 mg metoprolol (Selokeen) intravenously before CCTA. All participants
received sublingual nitroglycerine (nitrolingual) immediately before CCTA. Laboratory techni-
cians performed the coronary artery calcium score using semi-automatic software. All CT
scans were assessed by one of two experienced cardiac radiologists (NP, BKV), blinded for
findings at the baseline assessment. The CCTA scans were assessed for obstructive stenosis
(50%) comparing the diameters of the maximal stenosis to a reference diameter proximal
and distal to the stenotic area. The PWVmeasurements were collected by a different reader
(TLB) who was blinded for the CAC results. All relevant findings on CCT were discussed at
consensus meetings with a panel of at least two (sports) cardiologists and one radiologist.
Statistical analysis
Data are shown as mean ± SD for continuous variables where applicable, otherwise medians
and 25th and 75th percentiles (interquartile range [IQR]) are given. All categorical data are
reported as a percentage or absolute number. Student’s t test was used for differences between
groups and proportions between groups were compared by means of chi-square test.
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Sensitivity, specificity and positive- and negative predictive values of PWV for detecting rele-
vant CAD for both>8.3 m/s and>7.5m/s were calculated. The additional diagnostic value of
PWVmeasurements, compared to the SCORE parameters gender, age, systolic blood pressure,
total cholesterol, and ever smokers, was quantified using multivariate logistic modelling and
area under the receiver operating characteristic (ROC) curve (C-statistic) analysis. Statistical
significance was defined as a two-sided p-value< 0.05. The SPSS 20.0 (SPSS Inc., Chicago, IL,
USA) statistical software package was used for all calculations.
Results
Arterial PWVmeasurements were performed in 193 consecutive participants of the MARC
cohort (MARC participants 121–313). The characteristics of these 193 middle-aged sportsmen
are summarized in Table 1. Forty-seven (24%) participants were found to have CAD on CCT.
Forty-three participants had a CACS100 AU. The CCTA identified a total of 12 participants
with luminal narrowing50%, eight of whom also had a CACS100 AU. Those with CAD
were older (58.9 vs. 53.8 years, p<0.001), more often had hypertension (17% vs. 4%, p = 0.003),
had higher total cholesterol levels (5.7 vs. 5.4 mmol/l, p<0.05) and more often were (ever)
smokers (55 vs. 34% p = 0.008). Mean arterial PWV was 8.25 ± 1.9 m/s with significantly higher
PWV in the participants with CAD compared to those without CAD (8.9 vs. 8.0 m/s, p = 0.02).
For the PWV cut-off value>8.3m/s the sensitivity to detect CAD was 43%, specificity 69%,
positive predictive value 31% and negative predictive value was 79%. For the PWV cut-off
value>7.5m/s the sensitivity to detect CAD was 74%, specificity 45%, positive predictive value
30% and negative predictive value was 84%. In univariate analysis, age, (ever) smoking and
PWV were significantly associated with CAD with respective odds ratios (OR) of 1.15 per year
(95% CI 1.08–1.21, p<0.001), 1.62 (95% CI 1.2–2.3, p = 0.006) and 2.3 per m/s (1.1–4.9,
p = 0.01). The predictive capacity of PWV in relation to relevant CAD was characterized by a
C-statistic of 0.60 (95% CI 0.50–0.69, p = 0.050). The area under the curve (AUC) was 0.78
Table 1. Baseline characteristics.
Characteristic All N = 193 CAD N = 47 No CAD N = 146 P-value a
Age (years) 55.0 ± 6.6 58.9 ± 6.3 53.8 ± 6.3 <0.0001
Diabetes, n (%) 3(2) 1(2) 2(1) 0.71
Hypertension, n (%) 14 (7) 8 (17) 6(4) 0.003
BMI (kg/m2) 24.7±2.4 25.3±2.7 24.5±2.2 0.06
Ever smoked, n (%) 75(39) 26(55) 49(34) 0.008
Height (cm) 182±7.1 181±7.4 183±6.9 0.07
Weight (kg) 82±9.7 82±10.2 82±9.6 0.90
SBP (mmHg) 129±12.8 132±11.9 128±13.0 0.06
DBP (mmHg) 79±12.8 81±7.3 79±9.2 0.10
Total cholesterol (mmol/l) 5.4±0.9 5.7±0.8 5.4±0.9 0.048
PWV (m/s) 8.3±1.9 8.9±2.0 8.0±1.8 0.017
PWV >8,3 m/s, n (%) 65(34) 20(43) 45(31) 0.1
PWV >7,5 m/s, n (%) 116(60) 35(74) 81(55) 0.02
SCORE, median (IQR) 1 (1–2) 1 (1–2) 1(1–2) 0.26
Exercise tolerance (Watt) 307±47 303±46 315±51 0.2
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV, pulse wave velocity. Data are presented as mean ± SD,
proportions (%) or median values (interquartile range i.e. 25th and 75th percentile).
a P-value calculated with or Pearson χ2 or Fisher’s Exact Test (two sided) where appropriate, between cad and no cad groups.
doi:10.1371/journal.pone.0131895.t001
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(95% CI = 0.709 to 0.848) for the SCORE parameters gender, age, systolic blood pressure, total
cholesterol, and ever smokers. Adding PWVmeasurements to the SCORE model did not
appreciably change the AUC (model 2, AUC 0.78 95% CI 0.710–0.848, p = 0.99) indicating
limited additional diagnostic value of PWV assessed with a relatively new technique to SCORE
parameters.
Discussion
In this study performed in asymptomatic sportsmen aged 45 years or older, we found that the
sensitivity of Arteriograph derived PWVmeasurements for detecting subclinical CAD was
only fair when using a cut-off of 8.3 m/s, and fairly good for 7,5 m/s with a sensitivity of 74%.
When information on established risk factors (SCORE) was available, the additional value
of PWV appeared to be limited. However, as cholesterol is not always known, one might still
consider implementing arterial PWVmeasurements with the Arteriograph in the routine SME
of middle-aged sportsmen. The diagnostic sensitivity of PWV in identifying those with a high
risk of CAD is promising as 3 in 4 asymptomatic participants with subclinical CAD can be
identified. This may help justify referral of asymptomatic sportsmen for CCT based on avail-
able risk factors and PWVmeasurements.
Early identification of CAD should be an important goal in the pre-participation sports
evaluation of middle-aged persons. While sudden cardiac death in younger athletes (35 years
or younger) is mainly caused by cardiomyopathies, electrical heart disease and coronary anom-
alies, in older individuals it is predominantly caused by CAD (80%) [3, 31]. A recent paper on
cardiac arrest during long distance running implicated a causal role for demand ischemia in
athletes with (unknown) CAD [32]. Absence of coronary plaque rupture in these persons was
surprising because prior data [33] and expert consensus documents [31] have suggested that
exercise-induced acute coronary events result from atherosclerotic plaque disruption and coro-
nary thrombosis. This means that screening for relevant CAD is perhaps more important than
only performing exercise testing for a hemodynamically significant coronary stenosis. However
coronary calcium can only be regarded as a proxy measure for coronary artery disease.
Although it is unlikely to find someone with extensive coronary atherosclerosis who has no
CAC [34], persons with a CACS<100 AU can still suffer from a myocardial infarction [35,
36]. Although CAD has been considered the primary cause of exercise related SCD in individu-
als>35 years, there is evidence that diseases traditionally associated with SCD in young ath-
letes also play a significant role in this population [32, 37, 38]. Therefore, only screening for
CAD may not detect all middle-aged and older individuals at risk of SCD.
Our study is the first to evaluate the potential role of PWV to identify subclinical CAD in
asymptomatic middle-aged sportsmen that have undergone a routine SME. There is substantial
interest in refining cardiovascular risk prediction to better address preventative therapy among
those individuals considered to be at low or moderate risk according to current guidelines [39].
Therefore, additional cardiovascular biomarkers have been identified, including the mean
common carotid intima-media thickness, which has been shown to have clear additional value
in prediction of CV events on top of the FRS and ESC SCORE [40]. Although PWVmay have
potential as a biomarker [13–15], it remains unclear whether PWVmeasurements have addi-
tional clinical value in the daily practice of screening middle-aged sportsmen. Since the estab-
lished risk scores tend to underestimate cardiovascular risk in middle-aged sportsmen, as
demonstrated by Mohlenkamp et al. [6], we investigated whether aortic stiffness, as measured
by PWV, improved identification of sportsmen with subclinical atherosclerosis that warrants
further testing. However, this study has been critiqued for a higher proportion of smokers in
the self-selected study group. Our results support the association between established risk
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factors (including smoking), arterial stiffness and CAD on CCT in middle-aged sportsmen.
Our results are comparable to a recent meta-analysis including more than 17.000 participants
[21]. The authors stated that aortic PWV has value beyond conventional risk factors to predict
mortality and future cardiovascular events for younger individuals at intermediate risk
(improved risk prediction of 13%). Although it was still predictive for older individuals (hazard
ratio 1.23 for a subgroup above 70 years of age), the addition of PWV to the adjusted cardiovas-
cular prediction models only increased the C-statistics to a modest degree, suggesting that
PWV did not add much to standard risk assessment. A possible explanation is that systolic
blood pressure is a better surrogate of aortic stiffness in older people than in younger people
and the authors concluded that including PWV in models already containing systolic pressure
might limit the predictive value [21]. Furthermore another recent publication that was not
included in the meta-analysis showed comparable results for risk prediction of CAD with
PWV in a large cohort of elderly subjects [41]. The authors concluded that aortic stiffness mea-
surement in addition to FRS resulted in only limited reclassification rates and stated that
although aortic stiffness is associated with risk of CAD in elderly free of known CAD it pro-
vides no additional value in cardiovascular risk stratification.
Our study must be interpreted within the context of its limitations. First of all, we performed
measurements in a relatively small group of 193 participants. Although the number of consecu-
tive participants was considerable for a study of its kind, it remains a relatively small study of
selected men (all were Caucasian with at least college education). The fact that they consented
to participate after undergoing a SME may have led to additional selection bias (e.g. those with
a higher chance of cardiovascular disease because of a positive family history). In order to
avoid possible selection bias we compared the baseline criteria of the MARC population to a
large group (n = 725) of male recreational sportsmen aged45 years who recently underwent
a SME in the southern region of the Netherlands (Maxima Medical Centre, Veldhoven). The
groups were similar in age (mean age 55.0 vs. 54.3 years) systolic blood pressure (129 vs. 129
mmHg), body mass index (24.7 vs. 25.0 kg/m2), smoking status (current 3.1 vs. 5.1%), and fit-
ness level (workload 314 vs. 309 Watt), indicating that our group is representative for sports-
men that undergo a SME. Remarkably the consecutive participants who underwent additional
PWV had a slightly higher incidence of CAD compared to the whole cohort (24 vs. 18%,
p = 0.09). However, this difference was not significant (P = 0.09) and the consecutive partici-
pants who underwent additional PWV were similar in age (54.7 vs. 54.9 m/s, P = 0.4) SCORE
(both 1 with IQR 1–2), systolic blood pressure (SBP 127 vs. 129 mmHg P = 0.9), body mass
index (BMI 24.9 vs. 24.7 kg/m2 P = 0.7) smoking status (ever smoking 37% vs 39% P = 0.8) and
fitness level (workload 314 vs. 307 Watt P = 0.3).
Second, the Arteriograph is a relatively new device for the assessment of PWV. Although it
has been validated in some studies, [26, 29, 42], to our knowledge no prospective outcome
studies have been carried out with this device. Ideally, we should have performed a confirma-
tory study to compare our Arteriograph PWVmeasurements to the standard carotid-femoral
PWVmethod, however this was beyond the scope of this study. Therefore, before the Arterio-
graph can be implemented, we should acquire more clinical evidence that the Arteriograph can
provide additional prognostic value to the traditional CAD risk measurements, particularly in
older sportsmen who have a higher risk of CAD related events.
Third, we used established cut-off values for a population with optimal or normal blood
pressure and no identified CV risk factors. It is possible that the normal range however may be
different in our specific (trained) population. A recent study demonstrated that high intensity
aerobic interval training has the ability to reduce arterial stiffness in a cohort of treated hyper-
tensive women after 16 weeks of follow-up [43]. However this effect has neither been demon-
strated for moderate-intensity continuous exercise training nor has this been demonstrated in
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an asymptomatic male cohort free of known cardiovascular disease. Of note, the majority of
our participants are engaged in moderate intensity continuous exercise training (cycling, long
distance running).
In summary our study demonstrates that although limited additional value was found for
PWV evaluated with the Arteriograph on top of established risk factors to identify CAD, PWV
measurements may still have a role in the routine SME of middle-aged sportsmen to help iden-
tify those at a higher risk for relevant CAD. Larger studies of asymptomatic sportsmen in the
SME setting are required to verify that functional arterial measurements can have added clini-
cal value for cardiovascular risk stratification.
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